donwloadimg

Download App

Log in to access Online Inquiry
Multi-dimentional Analyses
Company Valuation Capital Tracking Short Selling Data
BMRN Biomarin Pharmaceutical
94.890
-0.180-0.19%
YOY
Do not show
Hide blank lines
(Q2)2022/06/30(Q1)2022/03/31(FY)2021/12/31(Q4)2021/12/31
Total revenue
6.4% 533.8M 6.85% 519.36M -0.76% 1.85B -0.51% 449.81M
Operating revenue
6.4% 533.8M 6.96% 519.36M 0.1% 1.85B -0.51% 449.81M
Cost of revenue
-3.1% 123.13M -2.66% 116.97M -10.25% 470.52M -5.06% 119.75M
Gross profit
9.62% 410.67M 9.97% 402.39M 2.96% 1.38B 1.25% 330.06M
Operating expense
2.09% 370.59M 9.64% 371.04M 1.55% 1.45B 6.77% 395.94M
Selling and administrative expenses
6.84% 196.8M 11.65% 194.6M 2.94% 759.4M 11.28% 217.56M
-Selling and marketing expense
8.42% 109.4M 11.36% 104.9M 0.42% 405.1M -- --
-General and administrative expense
4.92% 87.4M 11.99% 89.7M 5.98% 354.3M -- --
Research and development costs
-1.81% 158.19M 8.14% 160.84M 0.11% 628.79M 2.82% 161.09M
Depreciation amortization depletion
-11.82% 15.6M 1.3% 15.6M -0.48% 61.9M -7.27% 17.29M
-Depreciation and amortization
-11.82% 15.6M 1.3% 15.6M -0.48% 61.9M -7.27% 17.29M
Operating profit
244.55% 40.08M 14.12% 31.36M 19.05% -74.33M -46.92% -65.88M
Net non-operating interest income expense
-307.03% -1.35M -45.49% -1.99M 61.77% -4.86M -25.21% -2.1M
Non-operating interest income
-43.97% 2.51M -25.38% 1.82M -36.89% 10.48M -43.18% 1.75M
Non-operating interest expense
5.18% 3.86M 0.05% 3.81M -49.69% 14.74M -19.01% 3.85M
Total other finance cost
-- -- -- -- -- 593K -- --
Other net income (expense)
-310.22% -3.85M 3853.88% 104.85M -93.81% 3.85M -77.78% 1.41M
Special income (charges)
-- -900K 4708.7% 106M -114.55% -8M -- 0
-Less:Restructuring and merger&acquisition
-- 900K -13.04% 2M 77.78% 8M -- --
-Gain on sale of property,plant,equipment
-- 0 -- 108M -- 0 -- 0
Other non- operating income (expenses)
-246.98% -2.95M -234.5% -1.15M 65.72% 11.85M -73.26% 1.41M
Income before tax
146.19% 34.85M 477.7% 134.19M -78.04% -75.35M -65.67% -66.57M
Income tax
491.52% 7.19M 128.6% 13.39M 98.75% -11.27M 86.07% -8.68M
Net income
113.77% 27.66M 595.4% 120.8M -107.46% -64.08M -361.99% -57.9M
Net income continuous Operations
113.77% 27.66M 595.4% 120.8M -107.46% -64.08M -361.99% -57.9M
Minority interest income
Net income attributable to the parent company
113.77% 27.66M 595.4% 120.8M -107.46% -64.08M -361.99% -57.9M
Preferred stock dividends
Other preferred stock dividends
Net income attributable to common stockholders
113.77% 27.66M 595.4% 120.8M -107.46% -64.08M -361.99% -57.9M
Basic earnings per share
114.29% 0.15 560% 0.66 -107.37% -0.35 -366.67% -0.32
Diluted earnings per share
114.29% 0.15 600% 0.63 -107.73% -0.35 -366.67% -0.32
Dividend per share
Currency Unit
USDUSDUSDUSD
Accounting Standards
US-GAAPUS-GAAPUS-GAAPUS-GAAP
Audit Opinions
----Unqualified Opinion--

FY: Financial Year Annual Report, which is equivalent to the 10-K file disclosed by the listed company to the SEC.

Q: Quarterly report, which is equivalent to the 10-Q file disclosed by the listed company to the SEC, where Q1, Q2, Q3, and Q4 are single quarterly reports with a span of 3 months; Q6 and Q9 are cumulative quarterly reports, and Q6 is 6 months , Q9 is 9 months.

The MOM data from the Quarterly report,MOM=(current period - last period)/last period *100%

Company Overview More
BioMarin Pharmaceutical Inc. develops and commercializes therapies for people with serious and life-threatening rare diseases and medical conditions. Its commercial products include Vimizim, an enzyme replacement therapy for the treatment of mucopolysaccharidosis (MPS) IV type A, a lysosomal storage disorder; Naglazyme, a recombinant form of N-acetylgalactosamine 4-sulfatase for patients with MPS VI; and Kuvan, a proprietary synthetic oral form of 6R-BH4 that is used to treat patients with phenylketonuria (PKU), an inherited metabolic disease. The company’s commercial products also comprise Palynziq, a PEGylated recombinant phenylalanine ammonia lyase enzyme, which is delivered through subcutaneous injection to reduce blood Phe concentrations; Brineura, a recombinant human tripeptidyl peptidase 1 for the treatment of patients with ceroid lipofuscinosis type 2, a form of Batten disease; Voxzogo, a once daily injection analog of c-type natriuretic peptide for the treatment of achondroplasia; and Aldurazyme, a purified protein designed to be identical to a naturally occurring form of the human enzyme alpha-L-iduronidase. In addition, it develops valoctocogene roxaparvovec, an adeno associated virus vector, which is in Phase III clinical trial for the treatment of patients with severe hemophilia A; BMN 307, an AAV5 mediated gene therapy, which is in Phase 1/2 clinical trial to normalize blood Phe concentration levels in patients with PKU; and BMN 255 that is in Phase 1/2 clinical trial for treating primary hyperoxaluria. The company serves specialty pharmacies, hospitals, and non-U.S. government agencies, as well as distributors and pharmaceutical wholesalers in the United States, Europe, Latin America, and internationally. BioMarin Pharmaceutical Inc. has license and collaboration agreements with Sarepta Therapeutics, Ares Trading S.A., Catalyst Pharmaceutical Partners, Inc., and Asubio Pharma Co., Ltd. The company was incorporated in 1996 and is headquartered in San Rafael, California.
CEO: Bienaime M.B.A., MBA, Jean-Jacques
Market: NASDAQ
Hot List
TradeSearchNews
SymbolLatest price%Chg

Loading...